Adagene Unveils Data At SITC Highlighting Enhanced Therapeutic Index And Safety For Masked Anti-CTLA-4 SAFEbody ADG126, Showing Efficacy As Monotherapy And In Combination With Anti-PD-1 In Advanced MSS Colorectal Cancer
Adagene Unveils Data At SITC Highlighting Enhanced Therapeutic Index And Safety For Masked Anti-CTLA-4 SAFEbody ADG126, Showing Efficacy As Monotherapy And In Combination With Anti-PD-1 In Advanced MSS Colorectal Cancer
天演藥業在海豐國際公佈數據,突出增強的治療指數和安全性,對掩蔽的抗CTLA-4 SAFEbody ADG126顯示出在愛文思控股結直腸癌中的單藥和與抗PD-1聯合療效
Adagene Unveils Data At SITC Highlighting Enhanced Therapeutic Index And Safety For Masked Anti-CTLA-4 SAFEbody ADG126, Showing Efficacy As Monotherapy And In Combination With Anti-PD-1 In Advanced MSS Colorectal Cancer
天演藥業在海豐國際公佈數據,突出增強的治療指數和安全性,對掩蔽的抗CTLA-4 SAFEbody ADG126顯示出在愛文思控股結直腸癌中的單藥和與抗PD-1聯合療效
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。